1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanesand6-(aryl) -6-[alkoxyalkyl]-3azabicyclo[3.1.0]hexanes: A new series of potent and selective triple reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2534-2551

  Micheli, Fabrizio ^a   Cavanni, Paolo ^a   Arban, Roberto ^a   Benedetti, Roberto ^a   Bertani, Barbara ^a   Bettati, Michela ^a   Bettelini, Letizia ^a   Bonanomi, Giorgio ^a   Braggio, Simone ^a   Checchia, Anna ^a   Davalli, Silvia ^b   Fabio, Romano Di ^a   Fazzolari, Elettra ^a   Fontana, Stefano ^a   Marchioro, Carla ^b   Minick, Doug ^b,c   Negri, Michele ^a   Oliosi, Beatrice ^b   Read, Kevin D ^d   Sartori, Ilaria ^a   Tedesco, Giovanna ^b   Tarsi, Luca ^a   Terreni, Silvia ^a   Visentini, Filippo ^b   Zocchi, Alessandro ^a   Zonzin, Laura ^a   more..

^a Centre of Excellence for Drug Discovery in Psychiatry   (Italy)

^b GSK   (Italy)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (ARYL) 6 [ALKOXYALKYL] 3 AZABICYCLO[3.1.0]HEXANES DERIVATIVE; 6 (ARYL) 6 [ALKOXYALKYL] 3 AZABICYCLO[3.1.0]HEXANE DERIVATIVE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE; DOPAMINE TRANSPORTER; HEXANE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; FORCED SWIMMING TEST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY EPITHELIUM; LOCOMOTION; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PHARMACOPHORE; PREFRONTAL CORTEX; RAT; SIGNAL NOISE RATIO; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZABICYCLO COMPOUNDS; BINDING, COMPETITIVE; BIOGENIC MONOAMINES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MICE; MICRODIALYSIS; MICROSOMES, LIVER; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PREFRONTAL CORTEX; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949831859     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901818u     Document Type: Article

References (29)

1. (a) Kulkarni, S. K.; Dhir, A. Current investigational drugs for major depression. Exp. Opin. Investig. Drugs 2009, 18, 767-788.
2. (b) Wong, M. L.; Licinio, J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat. Rev. Drug Discovery 2004, 5, 136-151.
3. (c) Millan, M. J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 2004, 500, 371-384.
4. (d) Nemeroff, C. B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J. Psychiatry Res. 2007, 41, 189-206.
5. (a) Amt, J.; Christensen, A. V.; Hyttel, J. Pharmacology in vivo of the phenylindan derivative, Lu-19,005, a new potent inhibitor of dopamine, noradrenaline, and 5-hydroxytryptamine uptake in rat brain. Arch. Pharmacol. 1985, 329, 101-107.
6. (b) Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin. Investig. Drugs 2007, 16, 1365-1377.
7. (c) Rakofsky, J. J.; Holtzheimer, P. E.; Nemeroff, C. B. Emerging targets for antidepressant therapies. Curr. Opin. Chem. Biol. 2009, 13, 291-302.
8. (d) Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R.; et al. Antidepressant like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J. Pharmacol. Exp. Ther. 2008, 327, 573-583.
9. (e) Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003, 73, 3175-3179.
10. (f) Aluisio, L.; Lord, B.; Barbier, A. J.; Fraser, I. C.; Wilson, S. J.; Boggs, J.; Dvorak, L. K.; Letavic, M. A.; Maryanoff, B. E.; Carruthers, N. I. In vitro and in vivo characterization of JNJ7925476, a novel triple monoamine uptake inhibitor. Eur. J. Pharmacol. 2008, 587, 141-146.
11. (g) Bannwart, L. M.; Carter, D. S.; Cai, H. Y.; Choy, J. C.; Greenhouse, R.; Jaime-Figueroa, S.; Iyer, P. S.; Lin, C. J.; Lee, E. K.; Lucas, M. C. Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/ dopamine reuptake inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 6062-6066.
12. (h) Papakostas, G. I. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. 2006, 16, 391-402.
13. (i) Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. Antidepressant-like actions of DOV21,947: a "triple" reuptake inhibitor. Eur. J. Pharmacol. 2003, 461, 99-104.
14. (a) Scheel-Kruger, J.; Moldt, P; Watjen, F. Tropane-derivatives, their preparation and use. U.S. Patent 6395748, 2002;
15. (b) ScheelKruger, J.; Moldt, P; Watjen, F. Tropane-derivatives, their preparation and use. U.S. Patent 6288079, 2001;
16. (c) Scheel-Kruger, J.; Moldt, P; Watjen, F. Tropane-derivatives, their preparation and use. Patent WO 9730997, 1997;
17. (d) Scheel-Kruger, J.; Olsen, G. M.; Nielsen, E. O.; Dahl, B. H.; Jensen, L. H. Fused tropane derivatives as neurotransmitter reuptake inhibitors. Patent WO 9716451, 1997.
18. (a) Maestro, version 8.5.111; Schrodinger LLC: New York, 2006;
19. (b) BatchMin, version 9.6; Schrodinger LLC: New York, 2008;
20. (c) Phase, version 3.0.110; Schrodinger LLC: New York, 2006.
21. The research complied with national legislation and with company policy on the Care and Use of Animals and with related codes of practice.
22. Minick, D. J.; Rutkowske, R. D.; Miller, L. A. D. Strategies for successfully applying vibrational circular dichroism in a pharmaceutical research environment. Am. Pharmaceut. Rev. 2007, 10, 118-123.
23. Aptuit Limited, 3 Simpson Parkway, Livingston, West Lothian, EH54 7BH, Scotland; www.aptuit.uk.
24. Zocchi, A.; Fabbri, D.; Heidbreder, C. A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 2005, 387, 157-161.
25. Burchall, C. J.; Soroko, F. E.; Rigdon, G. C. Potentiation of the behavioral effects of 5-hydroxytryptophan by BW 1370U87, a selective monoamine oxidase-A inhibitor. Drug Dev. Res. 1992, 25, 209-213.
26. Martin, G. E.; Bendesky, R. J. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation. J. Pharmacol. Exp. Ther. 1984, 229, 706-711.
27. Bourin, M.; Chenu, F.; Prica, C.; Hascoet, M. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Heidelberg, Ger.) 2009, 206, 97-107.
28. Bonanomi, G.; Micheli, F.; Terreni, S. Azabicyclic compounds as serotonin, dopamine and norepinephrine re-uptake inhibitors and their preparation, pharmaceutical compositions and use in the treatment of depression. Patent WO 2008074716, 2008.
29. Bertani, B.; Bonanomi, G.; Di Fabio, R.; Fazzolari, E.; Micheli, F.; Tarsi, L. Preparation of 3-azabicyclo[3.1.0]hexane compounds as monoamine neurotransmitter re-uptake inhibitors. Patent WO 2009027293, 2009.